AbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks

Press/Media: Press / Media

PeriodAug 3 2017 → Aug 4 2017

Media coverage

37

Media coverage

  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outletPipelineReview
    CountrySpain
    Date8/4/17
    PersonsFred Poordad
  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outletNational AIDS Treatment Advocacy Project
    CountryUnited States
    Date8/4/17
    PersonsFred Poordad
  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outletPR Newswire
    CountryUnited States
    Date8/3/17
    PersonsFred Poordad
  • TitleABBVIE : Receives U.S. FDA Approval of MAVYRET(TM) (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outlet4 Traders
    CountryUnited States
    Date8/3/17
    PersonsFred Poordad
  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outletAriva.de
    CountryGermany
    Date8/3/17
    PersonsFred Poordad
  • TitleAbbVie Receives U.S. FDA Approval of MAVYRETâ„¢ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outletTickerTech.com
    CountryUnited States
    Date8/3/17
    PersonsFred Poordad
  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outletWTVM
    CountryGeorgia
    Date8/3/17
    PersonsFred Poordad
  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outletLive 5 WCSC
    CountryUnited States
    Date8/3/17
    PersonsFred Poordad
  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outletWBOC TV 16
    CountryUnited States
    Date8/3/17
    PersonsFred Poordad
  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outletWMBF
    CountryUnited States
    Date8/3/17
    PersonsFred Poordad
  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outletKAUZ
    CountryUnited States
    Date8/3/17
    PersonsFred Poordad
  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outlet14 WFIE
    CountryUnited States
    Date8/3/17
    PersonsFred Poordad
  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outletWMCTV.com
    CountryUnited States
    Date8/3/17
    PersonsFred Poordad
  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outlet35 WSEE
    CountryUnited States
    Date8/3/17
    PersonsFred Poordad
  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outletKWES NewsWest 9
    CountryUnited States
    Date8/3/17
    PersonsFred Poordad
  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outletKOTV
    CountryUnited States
    Date8/3/17
    PersonsFred Poordad
  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outletWTRF
    CountryUnited States
    Date8/3/17
    PersonsFred Poordad
  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outletWOWK
    CountryUnited States
    Date8/3/17
    PersonsFred Poordad
  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outletKTVN
    CountryUnited States
    Date8/3/17
    PersonsFred Poordad
  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outletKOAM TV
    CountryUnited States
    Date8/3/17
    PersonsFred Poordad
  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outletKHQ Right Now
    CountryUnited States
    Date8/3/17
    PersonsFred Poordad
  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outlet3 WRCB-TV
    CountryUnited States
    Date8/3/17
    PersonsFred Poordad
  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outletFox 19
    CountryUnited States
    Date8/3/17
    PersonsFred Poordad
  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outletWECT TV-6
    CountryUnited States
    Date8/3/17
    PersonsFred Poordad
  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outletKUSI.com
    CountryUnited States
    Date8/3/17
    PersonsFred Poordad
  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outletFox41.com
    CountryUnited States
    Date8/3/17
    PersonsFred Poordad
  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outlet19 Action News
    CountryUnited States
    Date8/3/17
    PersonsFred Poordad
  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outletWTOL-TV
    CountryUnited States
    Date8/3/17
    PersonsFred Poordad
  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outletKait 8
    CountryUnited States
    Date8/3/17
    PersonsFred Poordad
  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outletWVNS
    CountryUnited States
    Date8/3/17
    PersonsFred Poordad
  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outletNBC12 Online
    CountryUnited States
    Date8/3/17
    PersonsFred Poordad
  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outletKFMB-TV
    CountryUnited States
    Date8/3/17
    PersonsFred Poordad
  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outletWDAM-TV
    CountryUnited States
    Date8/3/17
    PersonsFred Poordad
  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outletWLBT
    CountryUnited States
    Date8/3/17
    PersonsFred Poordad
  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outletWTOC TV
    CountryGeorgia
    Date8/3/17
    PersonsFred Poordad
  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outletNews 9
    CountryUnited States
    Date8/3/17
    PersonsFred Poordad
  • TitleAbbVie Receives U.S. FDA Approval of MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT 1-6) in as Short as 8 Weeks
    Media name/outletKuam News 8
    CountryGuam
    Date8/3/17
    PersonsFred Poordad